Lincoln Capital’s AbbVie ABBV Stock Holding History

Lincoln Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Buy	1,047 +46	+5%	+$9.9K	0.05%	124
2026 Q1	$218K	Hold	1,001	–	–	0.04%	126
2025 Q4	$229K	Hold	1,001	–	–	0.04%	122
2025 Q3	$234K	Buy	+1,001	New	+$204K	0.04%	119
2019 Q1	–	Sell	-2,214	Closed	-$204K	–	73
2018 Q4	$204K	Buy	2,214 +10	+0.5%	+$879	0.11%	67
2018 Q3	$208K	Buy	+2,204	New	+$209K	0.1%	74

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Lincoln Capital's ABBV Position: Q2 2026 in Review

Lincoln Capital increased its AbbVie (ABBV) stake by 4.6% in Q2 2026, buying an estimated $9.9K and bringing the position to 1,047 shares worth $263K. The position accounts for 0.05% of the portfolio, ranked #124.

Lincoln Capital first reported a position in ABBV in Q3 2018 and has held it in 6 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lincoln Capital held 1,047 shares of AbbVie worth $263K as of Q2 2026.
Lincoln Capital bought 46 AbbVie shares in Q2 2026, an estimated $9.9K.
AbbVie made up 0.05% of Lincoln Capital's portfolio in Q2 2026, its #124 holding.
Lincoln Capital first reported a position in AbbVie in Q3 2018 and has held it in 6 quarters since.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lincoln Capital's 13F filing for Q2 2026, filed 7 Jul 2026.